Pfizer “Right-Of-Reply” Theory Reflects Interest From FDA, Firm Says
Executive Summary
Pfizer's amicus curiae brief articulating a "right-of-reply" for manufacturers reflects FDA's interest in the topic, Pfizer Senior Corporate Counsel Arnold Friede told an Institute for International Research conference on off-label use March 28 in Washington, D.C
You may also be interested in...
DTC Guidance Is High Priority In First Amendment Review, FDA Says
Direct-to-consumer ads are likely to be addressed by FDA early in the upcoming series of First Amendment guidances, Associate Deputy Chief Counsel Seth Ray said during the Food & Drug Law Institute Annual Education Conference in Washington, D.C. April 2
Pfizer Asks Supreme Court To Protect “Right Of Reply” In Cases Like ALLHAT
The ALLHAT study report illustrates why manufacturers need a clearly articulated "right of reply" under the First Amendment, Pfizer told the Supreme Court in an amicus curiae brief filed in support of Nike's appeal of Kasky v. Nike
Pharmacia Bextra Will Test COX-2 Market; Valdecoxib Clears FDA Nov. 16
Pharmacia's Bextra (valdecoxib) launch will test the hypothesis that the recent slow-down in the growth of Celebrex reflects a traditional nonsteroidal anti-inflammatory drug product lifecycle